ClinicalTrials.gg
CompletedNCT03055494ObePso-SUpdated Mar 10, 2023Results posted

Study to Explore the Effect of Secukinumab, Compared to Placebo, on Fat Tissue and Skin in Plaque Psoriasis Patients

A Phase 4 interventional study of Secukinumab and Placebo in Plaque Psoriasis, sponsored by Novartis Pharmaceuticals. Completed at 15 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-03-10.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
102
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 54 studies testing secukinumab in Psoriasis — 5 open to participants now, 5 under way, none of them phase 3. secukinumab · Psoriasis.

Enrollment
31st of 54
102 · median 124
Started
2017
with 4 others
Phase 4
17 of 54
4 open now
Registered
36th of 54
by date
Lead sponsor
37 of 54
Novartis Pharmaceuticals

Among the 54 studies testing secukinumab in Psoriasis, this one is the 31st largest by enrollment, is one of 5 that started in 2017, is one of 17 in phase 4, and was the 36th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

5 of the 54 studies testing secukinumab in Psoriasis are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About secukinumab

secukinumab: first FDA approval 2015 (COSENTYX), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies testing secukinumab in Psoriasis, or all of them as a file.
02

Study summary

This study provided a comparison of secukinumab to placebo with respect to skin inflammation as measured by skin exams in comparison to skin biopsies, adipose tissue and blood sample analyses.

Read the detailed description

This was a randomized, double-blind, placebo-controlled, multicenter design. Patients with moderate to severe plaque psoriasis received secukinumab 300 mg or placebo, with randomization stratified by body weight (\< 90 kg, ≥ 90 kg). There were 5 periods to the study: Screening (1 to 4 weeks), Double-blind Treatment Period (12 weeks), Double-blind Induction Period (4 weeks), Open-label Treatment Period (36 weeks), and Follow-up Period (1 week).

During the Double-blind Treatment Period, all patients attended study visits at Baseline, Weeks 1, 2, 3, 4, 8, and 12, and all doses of study treatment were self-administered at the study site. Patients underwent lesional (LS) and non-lesional (NL) skin biopsies at Baseline and Week 12. Assessments for the primary efficacy variable were performed at Week 12 before patients received their Week 12 dose. During the Double-blind Induction Period, patients randomized to placebo were switched to secukinumab 300 mg for the remainder of the study.

K16 and skin histology/biomarkers were assessed from skin biopsies. The Psoriasis Assessment and Severity Index (PASI) and the Investigator's Global Assessment modified 2011 scale (IGA mod 2011) were performed at specified study visits. Safety was monitored by vital signs, weight, waist circumference, body mass index (BMI), and clinical laboratory tests (serum chemistry, hematology, highsensitivity C-reactive protein (hs-CRP), hemoglobin A1c (HbA1c), homeostatic assessment of insulin resistance (HOMA-IR), viral serology, serum and urine pregnancy).

03

Conditions studied

  • Plaque Psoriasis

Browse trials for

Keywords

  • scalp psoriasis
  • plaque psoriasis
  • secukinumab
  • AIN457
  • biologic
  • monoclonal antibod
  • psoriasis
  • AIN457A
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written must be obtained before any assessment is performed
  • Clinical diagnosis of chronic plaque-type psoriasis at least 6 months prior to randomization
  • Moderate to severe plaque psoriasis as defined at baseline by:

    • ≥10% Body Surface Area (BSA) involvement and
    • PASI total score of ≥12 and
    • IGA mod 2011 score of ≥3 (based on a scale of 0-4)

Exclusion criteria

Exclusion Criteria:

  • Forms of diagnosed psoriasis other than chronic plaque psoriasis
  • Medication-induced or medication exacerbated psoriasis
  • Previous exposure to secukinumab or any other biologic drug directly targeting IL-17A or IL-17RA receptors
  • Ongoing use of prohibited treatments
  • Pregnant or nursing (lactating) women

Other protocol-defined inclusion/exclusion criteria may apply

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
102 participants (actual)

Study arms

  • Experimental
    Secukinumab

    Eligible patients received secukinumab 300 mg s.c. at randomization, Weeks 1, 2, 3 and 4 followed by monthly dosing up to Week 48

    Biological: Secukinumab

  • Placebo comparator
    Placebo

    Eligible patients received placebo at randomization, Weeks 1, 2, 3, 4, and 8. At Week 12, patients were switched to treatment with secukinumab 300 mg s.c. at Weeks 12, 13, 14, 15, and 16 followed by monthly dosing up to Week 48

    Biological: Placebo

Interventions

  • BiologicalSecukinumab

    Secukinumab 300 mg s.c. at randomization, Weeks 1, 2, 3, and 4 was followed by monthly dosing up to Week 48

    Also known as: AIN457

  • BiologicalPlacebo

    Placebo s.c. at randomization, Weeks 1, 2, 3, 4, and 8; secukinumab 300 mg s.c. at Weeks 12, 13, 14, 15, and 16 followed by monthly dosing up to Week 48

06

What researchers measure

Primary outcomes

  1. Number and Percentage of Participants With Response of Psoriasis Skin Lesions to Treatment at Week 12

    Response in skin histology/K16 expression to treatment (answered no)

    Time frame: 12 weeks

  2. Number of and Percentage of Participants Who Achieved Psoriasis Area and Severity Index 90 (PASI 90) at Week 12

    Psoriasis Area and Severity Index 90

    Time frame: 12 weeks

Secondary outcomes

  1. Number and Percentage of Participants With Response of Psoriasis Skin Lesions to Treatment at Week 52

    Response in skin histology/K16 expression to treatment (answered no)

    Time frame: 52 weeks

  2. Number of and Percentage of Participants Who Achieved Psoriasis Area and Severity Index 90 (PASI 90) at Week 52

    Psoriasis Area and Severity Index 90

    Time frame: 52 weeks

  3. Change in Systolic Blood Pressure From Baseline to Week 12

    Vital signs: summary statistics for change from baseline to Week 12

    Time frame: baseline, Week 12

  4. Change in Diastolic Blood Pressure From Baseline to Week 12

    Vital signs: summary statistics for change from baseline to Week 12

    Time frame: baseline, Week 12

  5. Change in Body Weight From Baseline to Week 12

    Vital signs: summary statistics for change from baseline to Week 12

    Time frame: baseline, Week 12

  6. Change in Glucose Level From Baseline to Week 12

    Vital signs: summary statistics for change from baseline to Week 12

    Time frame: baseline, Week 12

  7. Change in Insulin Level From Baseline to Week 12

    Vital signs: summary statistics for change from baseline to Week 12

    Time frame: baseline, Week 12

  8. Change in High-sensitivity C-reactive Protein (hsCRP) From Baseline to Week 12

    Vital signs: summary statistics for change from baseline to Week 12

    Time frame: baseline, Week 12

  9. Change in Homeostatic Model Assessment of Insulin Resistance (UNIT) (HOMA-IR) From Baseline to Week 12

    Vital signs: summary statistics for change from baseline to Week 12 Healthy Range: 1.0 (0.5-1.4) Less than 1.0 means you are insulin-sensitive which is optimal. Above 1.9 indicates early insulin resistance. Above 2.9 indicates significant insulin resistance.

    Time frame: baseline, Week 12

  10. Change in Hemoglobin A1c (HbA1c) Test for Diabetes Score From Baseline to Week 12

    Vital signs: summary statistics for change from baseline to week 12 For people without diabetes, the normal range for the hemoglobin A1c level is between 4% and 5.6%. Hemoglobin A1c levels between 5.7% and 6.4% mean you have a higher chance of getting diabetes. Levels of 6.5% or higher mean you have diabetes.

    Time frame: baseline, week 12

07

Results

Posted Mar 10, 2020
Limitations and caveats
Change in Body Mass Index (BMI) was not measured

Participant flow

A total of 133 patients were screened for the study, with 82 (61.7%) of these completing the screening phase.

Participant flow — Overall Study
MilestoneSecukinumab 300 mgPlacebo/Secukinumab 300 mg
Started5428
Completed4427
Not completed101
Withdrew: Lost to follow-up60
Withdrew: Physician decision20
Withdrew: Withdrawal by subject10
Withdrew: Adverse event01
Withdrew: Non-compliance with study treatment10

Outcome measures

PrimaryNumber and Percentage of Participants With Response of Psoriasis Skin Lesions to Treatment at Week 12

Response in skin histology/K16 expression to treatment (answered no)

Time frame:
12 weeks
Reported as:
Count of participants · Participants
Number and Percentage of Participants With Response of Psoriasis Skin Lesions to Treatment at Week 12
ParticipantsSecukinumab 300 mgPlacebo
Number and Percentage of Participants With Response of Psoriasis Skin Lesions to Treatment at Week 12431
Statistical analysis
  • Secukinumab 300 mg vs Placebo · 95% confidence interval · Difference in percentages: 76.1 · 95% CI 63.3 to 88.8Statistical analysis of "no" response of skin histology/K16 expression to treatment at Week 12
PrimaryNumber of and Percentage of Participants Who Achieved Psoriasis Area and Severity Index 90 (PASI 90) at Week 12

Psoriasis Area and Severity Index 90

Time frame:
12 weeks
Reported as:
Count of participants · Participants
Number of and Percentage of Participants Who Achieved Psoriasis Area and Severity Index 90 (PASI 90) at Week 12
ParticipantsSecukinumab 300 mgPlacebo
Number of and Percentage of Participants Who Achieved Psoriasis Area and Severity Index 90 (PASI 90) at Week 12290
Statistical analysis
  • Secukinumab 300 mg vs Placebo · 95% confidence interval · Difference in percentages: 55.8 · 95% CI 42.3 to 69.3
SecondaryNumber and Percentage of Participants With Response of Psoriasis Skin Lesions to Treatment at Week 52

Response in skin histology/K16 expression to treatment (answered no)

Time frame:
52 weeks
Reported as:
Count of participants · Participants
Number and Percentage of Participants With Response of Psoriasis Skin Lesions to Treatment at Week 52
ParticipantsSecukinumab 300 mgPlacebo/Secukinumab 300 mg
Number and Percentage of Participants With Response of Psoriasis Skin Lesions to Treatment at Week 523320
SecondaryNumber of and Percentage of Participants Who Achieved Psoriasis Area and Severity Index 90 (PASI 90) at Week 52

Psoriasis Area and Severity Index 90

Time frame:
52 weeks
Reported as:
Count of participants · Participants
Number of and Percentage of Participants Who Achieved Psoriasis Area and Severity Index 90 (PASI 90) at Week 52
ParticipantsSecukinumab 300 mgPlacebo/Secukinumab 300 mg
Number of and Percentage of Participants Who Achieved Psoriasis Area and Severity Index 90 (PASI 90) at Week 523120
SecondaryChange in Systolic Blood Pressure From Baseline to Week 12

Vital signs: summary statistics for change from baseline to Week 12

Time frame:
baseline, Week 12
Reported as:
Mean · mmHg
Change in Systolic Blood Pressure From Baseline to Week 12
mmHgSecukinumab 300 mgPlacebo
Change in Systolic Blood Pressure From Baseline to Week 12-2.6 ± 11.05-1.5 ± 11.43
SecondaryChange in Diastolic Blood Pressure From Baseline to Week 12

Vital signs: summary statistics for change from baseline to Week 12

Time frame:
baseline, Week 12
Reported as:
Mean · mmHg
Change in Diastolic Blood Pressure From Baseline to Week 12
mmHgSecukinumab 300 mgPlacebo
Change in Diastolic Blood Pressure From Baseline to Week 12-0.5 ± 7.92-0.2 ± 6.18
SecondaryChange in Body Weight From Baseline to Week 12

Vital signs: summary statistics for change from baseline to Week 12

Time frame:
baseline, Week 12
Reported as:
Mean · kg
Change in Body Weight From Baseline to Week 12
kgSecukinumab 300 mgPlacebo
Change in Body Weight From Baseline to Week 120.340 ± 2.54750.096 ± 3.8729
SecondaryChange in Glucose Level From Baseline to Week 12

Vital signs: summary statistics for change from baseline to Week 12

Time frame:
baseline, Week 12
Reported as:
Mean · mmol/L
Change in Glucose Level From Baseline to Week 12
mmol/LSecukinumab 300 mgPlacebo
Change in Glucose Level From Baseline to Week 120.027 ± 0.75050.332 ± 1.2933
SecondaryChange in Insulin Level From Baseline to Week 12

Vital signs: summary statistics for change from baseline to Week 12

Time frame:
baseline, Week 12
Reported as:
Mean · pmol/L
Change in Insulin Level From Baseline to Week 12
pmol/LSecukinumab 300 mgPlacebo
Change in Insulin Level From Baseline to Week 1215.037 ± 146.6361141.035 ± 446.2800
SecondaryChange in High-sensitivity C-reactive Protein (hsCRP) From Baseline to Week 12

Vital signs: summary statistics for change from baseline to Week 12

Time frame:
baseline, Week 12
Reported as:
Mean · mg/L
Change in High-sensitivity C-reactive Protein (hsCRP) From Baseline to Week 12
mg/LSecukinumab 300 mgPlacebo
Change in High-sensitivity C-reactive Protein (hsCRP) From Baseline to Week 12-5.010 ± 24.1279-1.273 ± 7.6405
SecondaryChange in Homeostatic Model Assessment of Insulin Resistance (UNIT) (HOMA-IR) From Baseline to Week 12

Vital signs: summary statistics for change from baseline to Week 12 Healthy Range: 1.0 (0.5-1.4) Less than 1.0 means you are insulin-sensitive which is optimal. Above 1.9 indicates early insulin resistance. Above 2.9 indicates significant insulin resistance.

Time frame:
baseline, Week 12
Reported as:
Mean · SI units
Change in Homeostatic Model Assessment of Insulin Resistance (UNIT) (HOMA-IR) From Baseline to Week 12
SI unitsSecukinumab 300 mgPlacebo
Change in Homeostatic Model Assessment of Insulin Resistance (UNIT) (HOMA-IR) From Baseline to Week 120.620 ± 6.01257.646 ± 26.5633
SecondaryChange in Hemoglobin A1c (HbA1c) Test for Diabetes Score From Baseline to Week 12

Vital signs: summary statistics for change from baseline to week 12 For people without diabetes, the normal range for the hemoglobin A1c level is between 4% and 5.6%. Hemoglobin A1c levels between 5.7% and 6.4% mean you have a higher chance of getting diabetes. Levels of 6.5% or higher mean you have diabetes.

Time frame:
baseline, week 12
Reported as:
Mean · scores
Change in Hemoglobin A1c (HbA1c) Test for Diabetes Score From Baseline to Week 12
scoresSecukinumab 300 mgPlacebo
Change in Hemoglobin A1c (HbA1c) Test for Diabetes Score From Baseline to Week 120.018 ± 0.18890.014 ± 0.2138

Adverse events

Collected over Up to 52 weeks. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Secukinumab 300 mg0/54 (0%)1/54 (1.9%)39/54 (72.2%)
Placebo/Secukinumab 300 mg0/28 (0%)1/28 (3.6%)25/28 (89.3%)
Most frequent serious events
Most frequent serious events
EventSecukinumab 300 mgPlacebo/Secukinumab 300 mg
Testis cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/541/28
Suicidal ideationPsychiatric disorders1/540/28
Most frequent other events
Showing 10 of 100
Most frequent other events
EventSecukinumab 300 mgPlacebo/Secukinumab 300 mg
NasopharyngitisInfections and infestations10/541/28
Upper respiratory tract infectionInfections and infestations7/541/28
InfluenzaInfections and infestations2/543/28
HypertensionVascular disorders0/543/28
Back painMusculoskeletal and connective tissue disorders4/540/28
CoughRespiratory, thoracic and mediastinal disorders4/542/28
BronchitisInfections and infestations0/542/28
Urinary tract infectionInfections and infestations2/542/28
Wound dehiscenceInjury, poisoning and procedural complications1/542/28
HyperlipidaemiaMetabolism and nutrition disorders0/542/28

Baseline characteristics

Age, Continuous
Age, Continuous(years)Secukinumab 300 mgPlaceboTotal
Mean41.5 ± 15.2050.4 ± 13.1044.5 ± 15.04
Sex: Female, Male
Sex: Female, Male(Participants)Secukinumab 300 mgPlaceboTotal
Female22830
Male322052
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Secukinumab 300 mgPlaceboTotal
Native American112
Unknown101
Caucasian441963
Black448
Asian336
Other112
08

Study locations

15 sites
  • Novartis Investigative Site
    Hot Springs, Arkansas 71913, United States
  • Novartis Investigative Site
    Los Angeles, California 90033, United States
  • Novartis Investigative Site
    Santa Ana, California 92701, United States
  • Novartis Investigative Site
    Atlanta, Georgia 30342, United States
  • Novartis Investigative Site
    Indianapolis, Indiana 46256, United States
  • Novartis Investigative Site
    East Windsor, New Jersey 08520, United States
  • Novartis Investigative Site
    West Orange, New Jersey 07052, United States
  • Novartis Investigative Site
    Buffalo, New York 14203, United States
  • Novartis Investigative Site
    New York, New York 10025 1737, United States
  • Novartis Investigative Site
    New York, New York 10065, United States
  • Novartis Investigative Site
    Portland, Oregon 97223, United States
  • Novartis Investigative Site
    Pittsburgh, Pennsylvania 15213-3403, United States
  • Novartis Investigative Site
    Webster, Texas 77004, United States
  • Novartis Investigative Site
    Murray, Utah 84107, United States
  • Novartis Investigative Site
    Norfolk, Virginia 23507, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2017 to primary completion in Apr 2018, 12 months.

Results were first posted in Mar 2020, 1 year 10 months after primary completion. A results delay was requested in Apr 2019.

Of 40 industry-sponsored phase 4 interventional studies under Psoriasis, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 29. This study's 12 months is below that.

Counting every sponsor, half of 115 studies reached it within 23 months; a quarter within 12 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 14, 2017
First posted
Feb 16, 2017
StartActual
Apr 18, 2017
Primary completionActual
Apr 25, 2018
CompletionActual
Feb 26, 2019
Results delay requested
Apr 18, 2019
Results first posted
Mar 10, 2020
Last update
Mar 10, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 10, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03055494
Responsible party
Sponsor
First posted
Feb 16, 2017
Start date
Apr 18, 2017
Primary completion
Apr 25, 2018
Completion
Feb 26, 2019
Results posted
Mar 10, 2020
Last update
Mar 10, 2023

Study contacts

Study Lead Novartis Pharmaceuticals
study director · Novartis

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Secukinumab

Start the discussion